Please login to the form below

Not currently logged in
Email:
Password:

Biohaven Pharmaceuticals

This page shows the latest Biohaven Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Biohaven gets FDA approval for migraine drug Nurtec ODT

Biohaven gets FDA approval for migraine drug Nurtec ODT

Biohaven Pharma has become the second drugmaker to bring an oral CGRP inhibitor to the US market for acute migraine, after the US Food and Drug Administration (FDA) approved its Nurtec ... Biohaven says Nurtec ODT (rimegepant) – its first commercial

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    1. Rimegepant from BioHaven Pharmaceuticals is an antagonist of calcitonin gene-related peptide (CGRP), recently approved in the US for the acute treatment of migraine, with prevention trials also ongoing. ... Eli Lilly/Dong Pharmaceuticals’ 5-HT1f

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics